BLAINJECTIONINJECTABLE
Approved
Apr 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
JOBEVNE (bevacizumab-nwgd) by Biocon is vascular endothelial growth factor-directed antibody interactions [moa]. Approved for colorectal cancer, non-small cell lung cancer, renal cell carcinoma. First approved in 2025.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JOBEVNE (bevacizumab-nwgd) is a monoclonal antibody biosimilar that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis. It is approved for colorectal cancer, non-small cell lung cancer, and renal cell carcinoma. The drug works by preventing new blood vessel formation that feeds tumors, starving them of oxygen and nutrients.
Growth
As a recently launched biosimilar in a crowded oncology space, JOBEVNE is in market-building phase with opportunity for commercial expansion teams to establish market presence against established branded and generic competitors.
Mechanism of Action
Vascular Endothelial Growth Factor-directed Antibody Interactions
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications (3)
Worked on JOBEVNE at Biocon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.